SEC Tracker
Get the app
MAZE · XBRL financial data

Maze Therapeutics financial statements, every quarter

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (MAZE's year ends in late December)

In thousands of dollarsMar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers—0——20,0000*
Research and development27,58028,10825,19027,570*34,14834,940
General and administrative7,8218,3667,77510,489*12,40513,095
Total operating expenses35,40136,47432,96538,059*46,55348,035
Operating income (loss)(35,401)(36,474)(32,965)(38,059)*(26,553)(48,035)
Interest expense————866931
Other income (expense)2,6152,795——2,3453,308
Income tax expense (benefit)—000*——
Net income (loss)(32,786)(33,679)(30,087)(34,568)*(24,208)(44,727)
Earnings per share, basic USD per share(1.15)(0.77)(0.66)—(0.45)(0.76)
Earnings per share, diluted USD per share(1.15)(0.77)(0.66)—(0.45)(0.76)
Weighted average shares, basic thousands of shares28,62843,79745,78053,396*53,89758,996
Weighted average shares, diluted thousands of shares28,62843,79745,78053,396*53,89758,996

Balance sheet

CSV

Fiscal quarters (MAZE's year ends in late December)

In thousands of dollarsMar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents294,374264,541316,773189,247198,766202,643
Marketable securities——67,162152,670153,616208,444
Marketable securities, non-current———18,11410,55683,821
Accounts receivable————20,000—
Prepaid and other current assets5,3336,6097,3677,8007,3979,336
Total current assets299,707271,150391,302349,717379,779420,423
Property and equipment, net6,3146,0065,5385,0444,6824,391
Right-of-use asset22,48321,70720,92020,11619,28518,442
Total assets332,840303,519422,058397,127419,710531,625
Accounts payable2,4043,6662,9181,7944,0132,212
Current portion of long-term debt————00
Total current liabilities18,61719,90022,11222,55621,23622,961
Long-term debt————38,83338,960
Lease liability, non-current21,14920,29119,41918,51117,55216,580
Total liabilities40,77241,28142,62242,16178,00978,501
Accumulated deficit(391,213)(424,892)(454,979)(489,547)(513,755)(558,482)
Total stockholders' equity292,068262,238379,436354,966341,701453,124
Total liabilities and equity332,840303,519422,058397,127419,710531,625
Common shares outstanding (cover page) thousands of shares43,79743,85148,11949,33655,34555,549

Cash flows

CSV

Fiscal quarters (MAZE's year ends in late December)

In thousands of dollarsMar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(32,786)(33,679)(30,087)(34,568)*(24,208)(44,727)
Stock-based compensation3,2263,237*3,864*6,073*7,1099,187*
Net cash from operating activities(29,516)(30,052)*(24,642)*(27,730)*(39,113)(15,053)*
Purchases of property and equipment299393*68*34*93107*
Net cash from investing activities(299)(393)*(66,883)*(103,387)*6,275(128,506)*
Net cash from financing activities127,378612*143,757*3,590*42,357147,436*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Maze Therapeutics202,6430*(15,053)*55.5M32.9 quarters 10-QJun 30, 2026
Theravance Biopharma219,76620,731(6,965)*51.9M55.7 quarters 10-QJun 30, 2026
Zevra Therapeutics122,14837,75610,047*59.5M— 10-QSep 30, 2026
aTYR PHARMA13,1400(9,511)*2.5M4.6 quarters 10-QSep 30, 2026
Arvinas88,000500(10,400)*65.5M13.0 quarters 10-QSep 30, 2026
CytoDyn16,359not reported(7,726)1.5B2.1 quarters 10-QAug 31, 2026
Arbutus Biopharma19,1711,014(6,018)*197.8M15.4 quarters 10-QJun 30, 2026
Cryoport279,17950,2205,214*50.7M— 10-QSep 30, 2026
Capricor Therapeutics20,935not reported(31,485)*58.1M7.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.